XML 23 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation
9 Months Ended
Sep. 30, 2016
Share Based Compensation [Abstract]  
Share-Based Compensation

NOTE 6 – Share-Based Compensation

The table below sets forth the line items where share-based compensation expense was recorded for the three and nine months ended September 30, 2016 and 2015:

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

Cost of goods sold

$

172

 

 

$

99

 

 

$

609

 

 

$

345

 

Selling, general and administrative

 

2,901

 

 

 

3,713

 

 

 

10,237

 

 

 

10,307

 

Research and development

 

684

 

 

 

287

 

 

 

1,991

 

 

 

1,003

 

Total share-based compensation expense

$

3,757

 

 

$

4,099

 

 

$

12,837

 

 

$

11,655

 

 

The table below sets forth share-based compensation expense by type for the three and nine months ended September 30, 2016 and 2015:

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

Stock options

$

304

 

 

$

517

 

 

$

1,212

 

 

$

1,999

 

Share grants

 

3,453

 

 

 

3,582

 

 

 

11,625

 

 

 

9,656

 

Total share-based compensation expense

$

3,757

 

 

$

4,099

 

 

$

12,837

 

 

$

11,655

 

 

Stock Options. Stock options generally vest in equal annual installments over a four-year period and expire eight years after the grant date.  Stock option expense was estimated on the date of grant using the Black-Scholes-Merton option pricing model.

There were no cash proceeds received from stock option exercises during the nine months ended September 30, 2016. 

The table below sets forth a summary of stock option activity for the nine months ended September 30, 2016:

Stock Options

 

Shares

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Term (years)

 

 

Aggregate Intrinsic Value

 

Outstanding at January 1, 2016

 

 

2,063

 

 

$

23.03

 

 

 

3.9

 

 

$

4,111

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited or expired

 

 

(210

)

 

 

22.39

 

 

 

-

 

 

 

-

 

Outstanding at September 30, 2016

 

 

1,853

 

 

$

23.10

 

 

 

3.6

 

 

$

2,712

 

Exercisable at September 30, 2016

 

 

1,726

 

 

$

22.86

 

 

 

3.5

 

 

$

2,712

 

 

The aggregate intrinsic value in the table above is before applicable income taxes and represents the amount option holders would have received if all options had been exercised on the last business day of the period indicated, based on our closing stock price.

As of September 30, 2016, total unrecognized share-based compensation expense related to unvested stock options, net of estimated forfeitures, was approximately $1.5 million, before income taxes, and is expected to be recognized over a weighted average period of approximately one year.

Share Grants. Restricted stock awards and restricted stock units generally vest in equal annual installments over a four-year period.  

The table below sets forth a summary of restricted stock awards and restricted stock units for the nine months ended September 30, 2016:

 

Share Grants

 

Shares

 

 

Weighted Average Grant-Date Fair Value

 

 

Aggregate Intrinsic Value

 

Non-vested at January 1, 2016

 

 

2,679

 

 

$

23.51

 

 

$

61,247

 

Granted

 

 

873

 

 

 

18.60

 

 

 

-

 

Vested

 

 

(789

)

 

 

19.54

 

 

 

15,227

 

Forfeited

 

 

(57

)

 

 

20.59

 

 

 

-

 

Non-vested at September 30, 2016

 

 

2,706

 

 

$

21.05

 

 

$

57,742

 

 

As of September 30, 2016, total unrecognized share-based compensation expense related to non-vested restricted stock awards and restricted stock units, net of estimated forfeitures, was approximately $49.2 million, before income taxes, and is expected to be recognized over a weighted average period of approximately three years.